New combo pill aims to tame stubborn high blood pressure

NCT ID NCT06682000

Completed Disease control Sponsor: Daewoong Pharmaceutical Co. LTD. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tested whether adding a second drug (DWC202314) to an existing one (DWC202404) helps people whose high blood pressure isn't controlled by the first drug alone. 192 adults with essential hypertension took part. The study is now complete, and results will show if the combination lowers blood pressure more effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DWC202404 and DWC202314 (combination drug therapy)
What this could lead to: If successful, this combination could offer a new treatment option for people with high blood pressure that isn't well controlled by a single medication.
What could go wrong: This is a completed Phase 3 trial, but results are not yet public. The combination may not prove significantly better than existing treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL HYPERTENSION HYPERTENSION

Contacts and locations

Locations

Hanyang University Medical Center

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.